Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Kevetrin seemed to stabilize CA-125 (ovarian cancer biomarker) in the lady with ovarian cancer who received 7 cycles / low doses of K.

Speaking of APR-246 and ovarian cancer, I see Aprea started a Phase I/II study in ovarian cancer in combination (just for you George) with platinum based chemo:

http://aprea.com/2014/dosing-initiated-in-phase-iii-clinical-trial-of-apr-246-in-ovarian-cancer/

Their first Phase I/II study was as monotherapy, against advanced blood and prostate cancer.

I guess their preclinical work showed it can re-sensitized ovarian cancer cells after they become refractory to platinum based chemo, so they decided a combo trial in ovarian cancer.